Analysts Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) PT at $13.80

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $13.80.

Several analysts recently weighed in on the company. TD Cowen initiated coverage on Orchestra BioMed in a research note on Wednesday, December 10th. They issued a “buy” rating on the stock. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, Barclays raised their price target on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th.

Orchestra BioMed Trading Up 2.2%

NASDAQ:OBIO opened at $4.12 on Friday. The firm has a market capitalization of $232.64 million, a P/E ratio of -2.26 and a beta of 0.62. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The company’s 50-day simple moving average is $4.15 and its 200 day simple moving average is $3.69.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock valued at $95,000 after buying an additional 7,036 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Orchestra BioMed in the 2nd quarter valued at approximately $122,000. Creative Planning purchased a new stake in Orchestra BioMed during the 2nd quarter valued at $40,000. Knott David M Jr purchased a new stake in Orchestra BioMed during the 2nd quarter valued at $268,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth $31,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.